Health Condition 1: F422- Mixed obsessional thoughts and acts
Conditions
Interventions
Intervention1: Risperidone: Antipsychotic drug, Dose: 1-3 mg, Route: oral, Frequency: Daily, Period: 8 weeks.
Control Intervention1: Aripiprazole: Antipsychotic drug, Dose: 2.5 mg-10 mg, Route: oral,
Sponsors
Government Medical College and Hospital
Eligibility
Inclusion criteria
Inclusion criteria: Patients fulfilling the criteria for OCD as per ICD-11 and on treatment with a dose within therapeutic range for one or more than one SSRIs for 12 weeks and current YBOCS =16
Exclusion criteria
Exclusion criteria: 1. Patients with evidence of dementia, organic brain disorders like epilepsy, tumours, neurological lesions, stroke 2. Patients on Tricyclic Antidepressants 3. Patients with Intellectual Disability 4. Patients with substance dependence except nicotine and caffeine 5. Patients with co-morbid major mental illness 6. Past history of augmentation with risperidone or aripiprazole 7. History of hypersensitivity/allergic reaction to risperidone and aripiprazole
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Compare clinical response to both the drugs which would be measured by reduction in the Y-BOCS and CGI scoresTimepoint: 0, 2, 4, 6, 8 weeks | — |
Secondary
| Measure | Time frame |
|---|---|
| Compare effect on QoL (measured by WHOQOL-BREF Hindi), sexual functioning (measured by ASEX), cognitive functioning (measured by HMoCA, DSST, TMT, DST), depressive and anxiety symptoms (measured by HDRS-17, HAM-A), and, also to assess the safety profile of both the drugs (measured by GASS)Timepoint: 0, 2, 4, 6, 8 weeks | — |
Countries
India
Contacts
Public ContactDr Shivangi Mehta
Government Medical College and Hospital
Outcome results
None listed